Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the 10 Unstoppable Stocks That Could Double Your Money.

TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the unstoppable stocks that could double your money. TuHURA announced its financial results for Q4 and the full year. The company is advancing its Phase 3 trial for IFx-2.0 as an adjunctive treatment for Merkel Cell Carcinoma/MCC under an FDA Special Protocol Assessment, with enrollment expected to conclude in mid-2027. To support its development pipeline, TuHURA acquired Kineta’s VISTA-inhibiting antibody, TBS-2025, for $10.5 million and appointed Dr. Craig Tendler to provide oversight for clinical operations.

Significant corporate milestones include the initiation of a Phase 1b/2a study for IFx-2.0 in patients with metastatic MCC of unknown primary origin and the presentation of data at ASH identifying the Delta Opioid Receptor as a target for overcoming immunotherapy resistance. For 2026, the company expects to receive Orphan Drug Designation for IFx-2.0 in MCC and plans to meet with the FDA regarding TBS-2025’s development in AML. Additionally, TuHURA aims to select its lead antibody-drug conjugate and initiate proof-of-concept studies within the second half of the year.

Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?

TuHURA Biosciences Inc. (NASDAQ:HURA) reported $3.6 million in cash and cash equivalents at the end of 2025, supplemented by $7.5 million received in early 2026. Annual R&D expenses rose to $20.5 million, reflecting increased investment in its clinical programs compared to the previous year. The company successfully raised $21.2 million through private placements and offerings during this period, supporting its ongoing efforts to develop novel immuno-oncology therapeutics.

TuHURA Biosciences Inc. (NASDAQ:HURA) is a clinical-stage biotech firm that develops novel immuno-oncology technologies for cancer treatment. The company was formerly known as Morphogenesis until December 2023.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.